said it expects fourth-quarter earnings to exceed consensus analyst expectations, due primarily to the successful launch of the company's new hepatitis C treatment.
Analysts had been expecting earnings of 29 cents a share, according to Thomson Financial/First Call.
The pharmaceutical company also said it expects to beat the consensus analyst estimate of $1.72 a share for the 2002 fiscal year.
Shares of ICN closed at $32.96 Wednesday on the
New York Stock Exchange
before the announcement.